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Abstract
Introduction Before any new methodology can be introduced
into the routine diagnostic setting it must be technically
validated against the established standards. To this end, a ring
study involving five international pathology laboratories was
initiated to validate chromogenic in situ hybridisation (CISH)
against fluorescence in situ hybridisation (FISH) and
immunohistochemistry (IHC) as a test for assessing human
epidermal growth factor receptor 2 (HER2) status in breast
cancer.
Methods Each laboratory performed CISH, FISH and IHC on its
own samples. Unstained sections from each case were also
sent to another participating laboratory for blinded retesting by
CISH ('outside CISH').
Results A total of 211 invasive breast carcinoma cases were
tested. In 76 cases with high amplification (HER2/CEP17 ratio
>4.0) by FISH, 73 cases (96%) scored positive (scores ≥ 6) by
'outside CISH'. For FISH-negative cases (HER2/CEP17 ratio
<2.0), 94 of 100 cases (94%) had CISH scores indicating no
amplification (score ≤ 5), and only three cases were positive by
CISH; in the three remaining cases, no CISH result could be
obtained. For cases with low-level amplification using FISH
(HER2/CEP17 ratio 2.0–4.0), 20 of 35 had CISH scores
indicating gene amplification. Inter-laboratory concordance was
also very high: 95% for normal HER2  copy number (1–5
copies); and 92% for cases with HER2  copy numbers ≥ 6.
CISH intra-laboratory concordance with IHC was 92% for IHC-
negative cases (IHC 0/1+) and 91% for IHC 3+ cases. Among
IHC 2+ cases, CISH was 100% concordant with samples
showing high amplification by FISH, and 94% concordant with
FISH-negative samples.
Conclusion These results show that CISH inter- and intra-
laboratory concordance to FISH and IHC is very high, even in
equivocal IHC 2+ cases. Therefore, we conclude that CISH is a
methodology that is a viable alternative to FISH in the HER2
testing algorithm.
Introduction
Human epidermal growth factor receptor 2 (HER2) is strongly
overexpressed in 20–30% of human breast cancers (the
HER2 gene is also known as ERBB2 or neu). HER2 is a 185
kDa transmembrane growth factor receptor with tyrosine
kinase activity, and has been shown to play a role in the signal
transduction of cell growth [1,2]. It has been shown in many
studies that overexpression of the HER2 protein correlates
with amplification of the HER2 gene [3-7]. A HER2-positive
status has been associated with a poor prognosis, including
aggressive disease and shorter survival [8], and there also is
evidence that HER2-positive tumours differ from HER2-nega-
tive tumours in their responsiveness to chemotherapy and hor-
monal therapy [9-14].
Trastuzumab (Herceptin), a humanised monoclonal antibody,
has been specifically developed to target HER2. Trastuzumab
has been shown unequivocally to confer a survival benefit in
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the treatment of women with HER2-positive breast cancer
[15,16]. As responsiveness to trastuzumab therapy is directly
linked to a patient's HER2 status, accurate determination of
HER2 status is essential for identifying patients who may ben-
efit from this form of treatment. It has been clearly shown that
HER2-positive patients, that is, patients whose tumours show
strong overexpression of HER2 as indicated by an immunohis-
tochemistry (IHC) score of 3+, and/or whose tumours show
HER2 gene amplification as determined by a positive fluores-
cence in situ hybridisation (FISH) result, derive the greatest
therapeutic benefit from treatment with trastuzumab [15,17].
Several different techniques have been used to determine
HER2 status in breast cancer specimens, including Southern,
northern and western blots, ELISA, and PCR. However, only
two technologies for HER2 status determination are currently
validated for use in the routine diagnostic setting: IHC, which
identifies HER2 protein expression on the cell surface, and
FISH, which determines the degree of HER2 gene amplifica-
tion. Both methods are highly specific and reproducible when
performed with a standardised and validated testing protocol.
IHC is far more widely used than FISH. The IHC test for HER2
is semi-quantitative, relating the intensity of the immunostain-
ing to the number of HER2 receptors on the tumour cell's sur-
face. The reagents for the IHC test for the identification of
HER2 are relatively inexpensive, the technique is quick, results
can be achieved using a conventional light microscope, and
the resulting stained slides are easy to preserve and archive.
In addition, IHC allows tumour cell morphology to be evaluated
by light microscopy. However, variations in methods can affect
the results of IHC staining, leading to equivocal results. Such
variations can include sample storage conditions, type of fixa-
tive used, duration of fixation and type of antibody used. The
scoring system for HER2 staining categorises tumours as 3+
(strongly positive staining), 2+ (moderately strong staining),
1+ (weak staining) and 0 (negative for staining). An IHC score
of 3+ is classified as positive for HER2 overexpression, but a
score of 2+ by IHC is generally considered equivocal; 0 or 1+
are considered HER2 negative. FISH identifies the number of
copies of the HER2 gene, normally in conjunction with the
number of chromosome 17 centromere copies, and is gener-
ally seen as being more quantitative than IHC. Furthermore, as
DNA is more stable than protein, pre-analytical factors have
less impact on test results compared with IHC. However, is
more expensive than IHC and takes longer to perform. It also
requires special training and access to a fluorescence micro-
scope, which are not available to many laboratories conduct-
ing routine diagnostic screening. In addition, the signals
produced by the FISH assay decay within a few weeks.
A HER2 testing algorithm has been proposed, and is recom-
mended in most national and international HER2 testing
guidelines [18]. Normally, IHC is performed as the initial test
to determine HER2 status. Eligibility is clear if the IHC score is
either 3+ or 0/1+; women with IHC 3+ tumours are eligible for
trastuzumab, whereas those with IHC 0/1+ tumours are not.
Women whose tumours produce an equivocal score (IHC 2+)
should be retested with FISH; a positive score by FISH is
required to confirm eligibility for trastuzumab. However, in
cases where FISH is used as the initial test, a positive FISH
score indicates eligibility for trastuzumab.
Due to the technical difficulties associated with FISH outlined
above, alternative methods of assessing HER2 gene amplifi-
cation status are being investigated. Chromogenic in situ
hybridisation (CISH) is similar to FISH in that it identifies the
degree of HER2 gene amplification, and has the same advan-
tages of a DNA-based assay. However, visualisation is
achieved using a peroxidase-based chromogenic reaction,
similar to IHC. Therefore, unlike FISH, positive signals can be
identified using an ordinary light microscope. The signal does
not decay, so results can be archived and stored. In recent
years, CISH has been evaluated and compared with the estab-
lished testing standards, IHC and FISH, in a number of studies
[19-23]. Most of these studies reported very high rates of con-
cordance (>85%) and thus agreement between these meth-
ods. Although it has been shown that when two observers
evaluate the same CISH stained slides, inter-observer variabil-
ity is low [19], inter-laboratory concordance of CISH has not
been extensively investigated. To this end, we initiated a ring
study involving five international pathology laboratories, to
technically validate CISH against the established standard
tests for HER2 status and to assess both the intra- and inter-
laboratory agreement of CISH.
Materials and methods
Tumour specimens
Each laboratory in the ring study provided 40–50 primary inva-
sive breast carcinoma specimens that had been successfully
pre-assessed at the original laboratory for HER2 status by
both IHC and FISH. Each laboratory included as many cases
with low-level amplification assessed by FISH as possible;
such cases are relatively rare, but were considered to be of
great interest for comparing results of FISH and CISH testing.
Each laboratory provided roughly 20 cases scored by FISH as
having no amplification, 15 cases scored as achieving high-
level amplification, and 6 cases scored as having low-level
amplification. Specimens were formalin-fixed (fixation time
ranged from 12–48 hours) and embedded in paraffin blocks.
Tissue sections for CISH analysis were 4–5 μm, mounted on
coated slides.
All specimens were coded for this study; in accordance with
the regulations provided by the medical ethical committees
from the participating institutes, the data cannot be linked to
patient information.Available online http://breast-cancer-research.com/content/9/5/R68
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Assays
The HercepTest (DakoCytomation, Glostrup, Denmark) was
used for IHC testing in most of the participating centres;
where alternative assays were used, these had been rigorously
evaluated using control cases. The results can be considered
to be equivalent to those achieved using the HercepTest
assay. The PathVysion kit (Vysis, Abbott, Illinois, USA) was
used for FISH testing and the SpoT-LIGHT CISH polymer
detection kit (Invitrogen, Carlsbad, California, USA) for CISH
testing. All assays were conducted as per the manufacturers'
instructions or, where TAB250 and CB-11 staining was used,
an internally validated and standardised staining protocol.
Study design
Five pathology laboratories, each from a different country, par-
ticipated in the study. Each laboratory conducted IHC, FISH
and CISH ('own CISH') on all their samples. Seven to eight
slides were prepared for each breast cancer specimen. Five
unstained slides from each sample were sent to the next labo-
ratory for CISH analysis ('outside CISH'; Figure 1). The labo-
ratory was blinded to the previous CISH, FISH or IHC results.
All scoring results were sent to one laboratory where the cor-
relation between 'outside' CISH and own CISH, FISH and IHC
results were calculated.
An additional 15 unstained slides, prepared from one repre-
sentative breast cancer sample (with areas of HER2-amplified
tumour cells and normal tissue) were also sent to the next lab-
oratory in the ring study. These slides were used to conduct a
pepsin-time course to determine the optimal digestion time for
the sample. The optimal pepsin digestion time was then used
in the preparation of the slides tested by CISH.
Scoring of results
Results for all assays were scored according to the manufac-
turers' instructions. The results of the IHC tests were scored
using the HercepTest scoring system (0–3+). The results of
FISH PathVysion kit were scored as follows: a sample was
classified as not amplified if it had a HER2/CEP17 ratio of
<2.0, low amplified if it had a HER2/CEP17 ratio of 2.0–4.0,
and high amplified if it had a HER2/CEP17 ratio of >4.0.
For CISH, the number of HER2 signals per nucleus was
counted (at 400× magnification) and categorised as <5 spots,
5 spots, 6 spots or >6 spots (tumours with a large cluster of
amplified spots per nucleus were also scored as >6 spots).
The scoring system was adapted from the protocol information
provided by Invitrogen. At least 30 tumour cells from each
specimen were analysed if the sample was deemed homoge-
neous, but at least 60 cells were analysed if the sample was
found to contain between 5 and 10 HER2 gene copies in
>50% of the area selected for evaluation. The proportion of
evaluable tumour cells and the ability to detect normal HER2
copy numbers in non-tumour cells were also recorded.
If CISH staining was not successful, this was indicated as 'no
signal'.
Additional quality assessments performed
Heterogeneous quality of the staining result may occur with
CISH. To evaluate the extent of heterogeneity in the study
results, the percentage of tumour cells with a good CISH
result was recorded for each case tested.
A significant advantage that CISH has over FISH is that histol-
ogy can be examined using a light microscope. Therefore, it
was possible to evaluate the morphology of the tumour cells in
this study by standard light microscopy. The morphology was
categorised as excellent, good, reasonable or poor.
Results
A total of 211 cases were scored. Typical CISH results are
shown (Figure 2). Gene copies can be identified as dots in the
nuclei of the cells.
Inter-laboratory correlation between FISH and CISH
The correlation between the results of FISH testing in the
sending laboratory and CISH in the blinded laboratory receiv-
ing the unstained slides (outside CISH) is summarised in
Table 1. Most cases (70 of 76 cases; 92%) that had a high
level of amplification by FISH (HER2/CEP17 ratio of >4.0),
were scored as having high amplification by CISH (copy
number >6). Three cases (4%) were scored by CISH as hav-
ing a HER2 copy number of 6, indicating a low level of gene
amplification. Three more cases (4%) were negative for ampli-
fication by CISH; two of these cases contained five HER2
gene copies and one contained <5 gene copies as deter-
mined by CISH.
Figure 1
Study design Study design. Each of the 5 centres forward 5 blinded, unstained slides 
from each sample to the next centre for chromogenic in situ hybridisa-
tion (CISH) analysis (thick arrows). Results from each centre are 
reported back to centre A every 2 months (thin arrows).Breast Cancer Research    Vol 9 No 5    van de Vijver et al.
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One hundred of the 211 cases evaluated had previously been
shown to have a HER2/CEP17 ratio of <2.0 as determined by
FISH, and were HER2 negative. Of these cases, 94 (94%)
had ≤ 5 copies of the HER2 gene (no amplification) by CISH.
Only three of the 100 FISH-negative cases were scored as
positive for HER2 gene amplification by CISH. In three cases,
no signal could be obtained by CISH.
Thirty-five of the 211 cases included in the study were consid-
ered low-amplified cases (FISH HER2/CEP17 ratio between
2.0–4.0); of these, 20 cases had an amplified HER2 gene
copy number by CISH, with five containing 6 HER2 gene cop-
ies and 15 having >6 copies. In 15 of the 30 cases, CISH did
not detect HER2 gene amplification and of these, 11 were
found to have a HER2 copy number <5 and four had a copy
number of 5.
Inter-laboratory concordance of CISH results
Table 2 shows the correlation between CISH performed in the
sending laboratory (own CISH) and CISH performed at the
receiving laboratory (outside CISH).
Ninety-two cases had a high level of amplification (>6 copies
per cell) by own CISH, 85 (92%) demonstrated some degree
of HER2 gene amplification (≥6 copies per cell) by outside
CISH. Seventy-eight of these cases had >6 HER2 copies per
cell and seven had 6 copies per cell as determined by outside
CISH. Seven cases (8%) were classified as negative for ampli-
fication (≤5 copies per cell) by outside CISH. Four of these
cases had <5 HER2 copies per cell and three had 5 copies.
Of the 101 cases that had at least a low-level of HER2 gene
amplification (≥6 copies per cell) by own CISH, 88 cases also
scored positive for amplification by outside CISH (87%), six
cases scored 5 copies per cell by outside CISH, and seven
cases scored <5 signals per cell.
Most cases (96 of 101 cases; 95%) that scored <5 copies
per cell by own CISH, had no amplification (≤5 copies per cell)
by outside CISH. Ninety-four of these cases scored <5 HER2
copies per cell and two had 5 copies per cell. One case
scored 6 HER2 copies per cell as determined by 'outside
CISH', and three were scored as having >6 copies per cell.
Figure 2
Chromogenic in situ hybridisation (CISH) on a breast carcinoma with normal, low and high HER2 copy number (1000×) (a) chromogenic in situ hybridisation (CISH) on a breast carcinoma with normal HER2 copy number (1000×). An average of two darkly brown stain-
ing copies of the HER2 gene can be seen in each tumour cell. (b) CISH on a breast carcinoma with low level HER2 gene amplification (1000×). An 
average of 6 copies of the HER2 gene can be seen in each tumour cell. (c) CISH on a breast carcinoma with high level HER2 gene amplification 
(1000×). Large clusters of darkly brown staining HER2 copies can be seen in each tumour cell. It is not possible to count the exact number of HER2 
gene copies; this is the usual result seen in tumours with high HER2 gene amplification.
Table 1
Inter-laboratory correlation between FISH and CISH
CISH (number of signals)
FISH HER2/CEP17 ratio <5 5 6 >6 No signal n
<2.0 91 3 0 3 3 100
2.0–4.0 11 4 5 15 0 35
>4.0 1 2 3 70 0 76
Total 103 6 8 88 3 211
CISH, chromogenic in situ hybridisation; FISH, fluorescence in situ hybridisation; HER2, human epidermal growth factor receptor 2.Available online http://breast-cancer-research.com/content/9/5/R68
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Out of the 105 cases scored as negative for HER2  gene
amplification (≤5 copies per cell) by own CISH, 97 also
scored as negative by outside CISH (92%). One case had 6
HER2 copies per cell as determined by outside CISH, and five
cases had >6 copies. No signal was detected in a further two
cases.
Intra-laboratory correlation between IHC and CISH
The correlation between IHC and CISH performed in the same
laboratory is shown in Table 3. Of the 211 cases included in
this study, 86 were scored as HER2 3+ by IHC. Of these, 78
(91%) were scored as having HER2 gene amplification by
CISH (≥6 copies per cell). Of the 50 cases scored as HER2
0 or 1+, 46 (92%) showed normal HER2 copy number by
CISH. Of the 75 cases scored as HER2 2+ by IHC, 20 (27%)
cases showed HER2 gene amplification as assayed by CISH.
Intra-laboratory correlation between FISH and own CISH 
in IHC 2+ cases
According to the current HER2 testing algorithm, FISH is used
to confirm IHC 2+ cases. All seven IHC 2+ cases scored as
having high levels of amplification by FISH were also scored
as highly amplified (>6 copies) by CISH (100%) (Table 4). Of
the 47 IHC 2+ cases scored as not amplified by FISH, 44
(94%) were negative by CISH (≤ 5). Of 18 IHC 2+ cases with
low amplification by FISH, 12 were negative by CISH (11 had
<5 HER2 copies per cell, one had 5 copies per cell), two had
6 copies per cell, and four were scored as having >6 copies
per cell.
Other quality parameters of the CISH test
Good CISH staining was seen for 75–100% of cells in 65%
of the cases examined, 50–75% of cells in 17% of cases, 25–
50% of cells in 11% of the cases and 0–25% of cells in 7%
of cases.
Tumour cell morphology was found to be excellent in 15.5% of
cases, good in 67% of cases, and reasonable in 15% of cases
(Table 5). Poor tumour cell morphology was observed in only
2.5% of cases.
Table 2
Inter-laboratory correlation between 'own CISH' and 'outside CISH'
Outside CISH (number of signals)
Own CISH (number of signals) <5 5 6 >6 No signal n
<5 94 2 1 3 1 101
50 1 0 2 1 4
63 3 0 3 0 9
>6 4 3 7 78 0 92
No signal 0 0 0 1 1 2
Total 101 9 6 87 3 208
CISH, chromogenic in situ hybridisation.
Table 3
Intra-laboratory correlation between CISH and IHC
IHC
Own CISH (number of signals) 0/1+ 2+ 3+ n
<5 44 44 6 104
5 21 1 4
6 15 3 9
>6 21 5 7 5 9 2
No signal 10 1 2
Total 50 75 86 211
CISH, chromogenic in situ hybridisation; IHC, immunohistochemistry.Breast Cancer Research    Vol 9 No 5    van de Vijver et al.
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Discussion
Accurate assessment of HER2 status is essential for identify-
ing patients who are candidates for therapy with the anti-
HER2 monoclonal antibody trastuzumab. A rapid and accurate
test for HER2 status is needed because an increased number
of treatment decisions are based on the HER2 status of a
patient's disease. In particular, increasing evidence suggests
that response to certain forms of hormone treatment and
chemotherapy are dependent on a patient's HER2 status [9-
14]. The results of our multicentre ring study show that CISH
is a reliable test for the assessment of HER2  gene copy
number.
The study demonstrates excellent correlation between FISH
and CISH results, with 92% of cases scored as having high-
level amplification by FISH also scoring as having high-level
amplification by CISH. In addition, 94% of cases which were
shown to have a normal HER2 gene copy number by FISH
appeared to lack HER2 gene amplification by CISH. Inter-lab-
oratory concordance with CISH was similar to that seen
between FISH and outside CISH; 94% for ≤5 HER2 copies
per cell and 92% for ≥6 HER2 copies per cell.
Intra-laboratory correlation of IHC with CISH was also good
for cases scored as 3+ and 0 or 1+ by IHC (91% and 92% of
cases respectively). Twenty (27%) of the 75 cases scored as
HER2 2+ by IHC showed HER2  gene amplification as
assayed by CISH. This is in agreement with the findings of
other studies comparing HER2 overexpression with the
degree of HER2 gene amplification. In these studies, the per-
centage of tumours with a HER2 IHC 2+ score and gene
amplification was approximately 25% [12,25,26].
Accurate scoring of cases with low-level HER2 gene amplifi-
cation is technically challenging. Therefore, a high number of
cases with a HER2/CEP17 ratio of 2.0–4.0 were specifically
included for evaluation in this study. According to the FISH
scoring guidelines, these cases are positive for HER2 gene
amplification. However, 43% of cases scored as low level of
amplification by FISH, but scored as non-amplified by CISH.
Further detailed analyses should be conducted in this area to
clarify this result. However, it should be noted that breast car-
cinomas with a low degree of HER2 gene amplification are
rare (estimated to be 1–3% of all carcinomas), and inter-
observer variability is greatest in this category of samples.
Indeed, three out of seven cases with low-level amplification
assessed by FISH included in this study gave different results
when re-assessed by FISH in another laboratory (data not
shown). A recent inter-observer study for FISH showed that,
although agreement was excellent for tumours with normal
HER2 gene copy numbers or HER2 gene amplification, there
was marked inter-observer variability in these 'borderline
cases' [27]. Recently, a consensus panel has proposed
adapted scoring guidelines for HER2 testing. An important
recommendation from this panel was to consider reporting
breast cancer cases with a HER2/centromer chromosome 17
ratio between 1.8 and 2.2 as borderline [28]. Using this
adapted scoring guideline, a tumour is assessed as HER2
Table 4
Correlation between FISH and own CISH in IHC 2+ samples
Own CISH (number of signals)
FISH <5 5 6 >6 n
<2.0 44 0 3 0 47
2.0–4.0 11 1 2 4 18
> 4 . 0 00077
Total 56 1 5 11 73
CISH, chromogenic in situ hybridisation; FISH, fluorescence in situ hybridisation; IHC, immunohistochemistry.
Table 5
Tumour cell morphology
Morphology
Excellent 33/214 15.5%
Good 144/214 67.0%
Reasonable 32/214 15.0%
Poor 5/214 2.5%Available online http://breast-cancer-research.com/content/9/5/R68
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amplified when the ratio is more than 2.2; or when the absolute
number of HER2 gene copies is more than six.
The key to understanding FISH/CISH discrepancy in cases
with low-level amplification lies in the nature of the two tests.
A significant difference between FISH and CISH is that in the
most commonly used FISH assay, 2-colour FISH, the copy
number of the HER2 gene and of the centromere of chromo-
some 17 (CEP17) are assessed simultaneously. The signal
from the centromere probe functions as an internal control; the
final FISH score is based on a ratio of the signals from the two
probes. Conversely, in the CISH assay, the copy number of
HER2  is assessed directly. When classifying tumours with
one to four copies, or with >10 copies of HER2 by CISH, the
HER2 status of the sample is clear. However, in cases with
HER2 copy numbers in the range of 4–10, the HER2/CEP17
ratio may be of importance. Some discrepancies between
FISH and CISH may also be explained for polysomic cases
where the FISH assay might indicate a negative testing result,
as the HER2/CEP17 ratio is calculated, while CISH indicates
a HER2-positive testing result as the numbers of HER2 sig-
nals are assessed. In general, we have also noted that the
inter-observer variability in scoring cases with mid-range
HER2 copy numbers is relatively large, and also that inter-
observer variability in scoring HER2/CEP17 ratio with FISH is
considerable (unpublished results). According to the Invitro-
gen scoring system for CISH, supplied by the manufacturer at
the start of this study, a score of ≤5 HER2 copies per cell indi-
cates no amplification, whereas a score of ≥6 HER2 copies
indicates amplification. This meant that classification of cases
with an average CISH score of 5–6 was unclear. However,
since this study, Invitrogen has updated its scoring system to
specify that a score of >5 signals per cell should now be con-
sidered indicative of HER2 gene amplification. As we wished
to be able to categorize the subgroups in this borderline cate-
gory more precisely, scoring 5 copies and 6 copies as sepa-
rate categories was part of the study design. We believe that
obtaining a reliable CISH result for these borderline cases is
no more problematic than obtaining a reproduced FISH result
for such cases. A practical approach to this problem is to
count at least 60 nuclei when the number of HER2 copies
ranges from 4–10, and to consider adding CISH using a
CEP17 probe on a consecutive slide to confirm the result.
Alternatively, and where possible, dual-colour FISH with
probes for HER2 and CEP17 can be considered. It is to be
hoped that it will be possible to analyze the studies showing
benefit of trastuzumab therapy in the adjuvant setting for the
benefit of the subgroup of HER2 low-level/borderline ampli-
fied tumours. This may help to better define the analytical
approach to this category of tumours.
When own CISH was compared with FISH in determining the
HER2 status of IHC 2+ cases, there was 100% concordance
for HER2-positive samples and 94% for HER2-negative sam-
ples. The good intra-laboratory correlation of FISH with CISH
suggests that CISH could potentially be used in place of FISH
to determine the HER2 status of equivocal cases by IHC. As
both tests produce similar results in the retesting of equivocal
IHC cases, CISH could potentially fulfil the same role as FISH
in the HER2 testing algorithm.
CISH displayed high inter-laboratory concordance, showing
that results are reproduced between laboratories. Correlation
between own CISH and outside CISH was similar to that
observed between FISH and outside CISH with 95% con-
cordance for cases with <5 HER2 copies per cell and 92% for
cases with >6 HER2 copies per cell. The most notable dis-
crepancies with CISH in a few cases are probably the result of
technical problems with the staining procedure or with the
interpretation of the results. This highlights the need for train-
ing before any technology is used for the first time. However,
the excellent inter-laboratory correlation of CISH results high-
lights its potential as a method for testing HER2-status, even
in those laboratories unfamiliar with using CISH.
As can be seen from our results, this study includes cases with
a HER2 IHC3+ score but without HER2 gene amplification
(as detected by CISH); and cases with a HER2 IHC0/1+
score and with HER2 gene amplification (as detected by
CISH). The number of discrepancies was very similar if FISH
was used instead of CISH (data not shown). In view of the clin-
ical consequences of accurate HER2 status assessment for
many patients, it should be considered to test CISH (or FISH)
alongside IHC either as a diagnostic routine or as part of a
quality assurance program in each lab.
The pre-treatment of tissue sections, especially the pepsin
digestion time, was a critical step in achieving a good CISH
result. Like FISH, the optimal pepsin digestion time differs
between tumours. For practical reasons, the pepsin digestion
time used in the preparation of received slides was calculated
in each laboratory on the basis of a pepsin time course
performed on one representative tumour provided by the
sending laboratory. However, it is possible that this was not
the optimal value for all tumour samples, and as a result it was
likely that in some cases no HER2 signal would be detected.
For such cases, it was determined that the CISH test should
be repeated after adjustment of the pepsin digestion time.
Using this strategy, a good result was obtained in 99% of the
cases (208 out of 211). In all cases, the percentage of tumour
cells for which HER2 copy number could be assessed by
CISH was recorded; this percentage was >50% for most
cases (data not shown). There were no cases in this series
where noticeable heterogeneity in the number of HER2 sig-
nals per tumour cell was observed.
An advantage of CISH over FISH is that invasive tumour cells
can be easily identified using a light microscope, provided that
the morphology of the tissue is good following CISH staining.
More than 80% of the tumours examined to date in this studyBreast Cancer Research    Vol 9 No 5    van de Vijver et al.
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had either good or excellent morphology, illustrating this ben-
eficial aspect of CISH testing.
Conclusion
This validation ring study demonstrates that CISH is a very
powerful test for the determination of HER2 gene copy num-
bers in breast cancer specimens. Moreover, CISH also has
significant advantages over FISH, which is considered to be
the reference standard for determination of HER2 gene ampli-
fication. These results are similar to the findings of other stud-
ies that have evaluated CISH [19-24]. The concordance of
CISH with FISH in this study is especially encouraging as
CISH tests were performed in a different laboratory to the one
in which the tumour sections were prepared, which adds a
greater level of significance to these trial results. Therefore, in
view of these results, we suggest that CISH can be used as
an alternative method to FISH in the current HER2 testing
algorithm (Figure 3).
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